Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263934 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
A Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT05263934: Active Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis, sponsored by GlaxoSmithKline.
NCT05263934 is a Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 163 participants, below the 582-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05263934, a Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Primary Outcome
Participants must be in remission at both Weeks 36 and 52.
Conditions Studied
Interventions
- BIOLOGICAL Depemokimab
- BIOLOGICAL Mepolizumab
- DRUG Placebo matching mepolizumab
- DRUG Placebo matching depemokimab
Study Locations (20)
Other
- GSK Investigational Site - La Plata
- GSK Investigational Site - San Miguel de Tucumán
- GSK Investigational Site - Graz
- GSK Investigational Site - Brussels
- GSK Investigational Site - Leuven
- GSK Investigational Site - São Paulo
- GSK Investigational Site - Beijing
- GSK Investigational Site - Guangzhou
- GSK Investigational Site - Hefei
Pennsylvania
- GSK Investigational Site - Philadelphia
- GSK Investigational Site - Pittsburgh
Ontario
- GSK Investigational Site - Toronto
- GSK Investigational Site - Toronto
Colorado
- GSK Investigational Site - Denver
Florida
- GSK Investigational Site - Gainesville
Minnesota
- GSK Investigational Site - Rochester
New York
- GSK Investigational Site - New York
North Carolina
- GSK Investigational Site - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2026-10-27 |
| Phase | Phase 3 |
What the registry record for NCT05263934 still lists
NCT05263934 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 582-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Eosinophilic Granulomatosis With Polyangiitis appearing as the primary indexed condition, and to 4 interventions - of which Depemokimab is the first listed.
NCT05263934 names 20 study sites across 10 states, led by Other, Pennsylvania, Ontario.
Frequently Asked Questions
What is clinical trial NCT05263934 about?
NCT05263934 is a clinical study titled "Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)". This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
What is the current status of trial NCT05263934?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2022-07-14. Estimated completion is 2026-10-27.
What conditions does trial NCT05263934 study?
This clinical trial studies the following conditions: Eosinophilic Granulomatosis With Polyangiitis.
What interventions are being tested in trial NCT05263934?
The interventions under investigation include: Depemokimab (BIOLOGICAL), Mepolizumab (BIOLOGICAL), Placebo matching mepolizumab (DRUG), Placebo matching depemokimab (DRUG).
Who is sponsoring clinical trial NCT05263934?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263934 being conducted?
This trial has 20 study locations across Colorado, Florida, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Granulomatosis With Polyangiitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI